THE SEROTONIN SYNDROME-ASSOCIATED WITH PAROXETINE, AN OVER-THE-COUNTER COLD REMEDY, AND VASCULAR-DISEASE

被引:88
作者
SKOP, BP [1 ]
FINKELSTEIN, JA [1 ]
MARETH, TR [1 ]
MAGOON, MR [1 ]
BROWN, TM [1 ]
机构
[1] WILFORD HALL USAF MED CTR,DEPT PSYCHIAT,2200 BERGQUIST DR,ST 1,LACKLAND AFB,TX 78236
关键词
DEXTROMETHORPHAN; ENDOTHELIUM; PAROXETINE; SEROTONIN; SEROTONIN SYNDROME; VASCULAR DISEASE;
D O I
10.1016/0735-6757(94)90031-0
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
There is a new, potentially fatal disorder that is infrequently reported. The apparent rareness may be because of a lack of recognition of the syndrome or its predisposing factors. Fluoxetine (Prozac, Dista Products Co, Division of Eli Lilly Co, Indianapolis, IN), sertraline (Zoloft, Roerig Division, Pfizer Inc, New York, NY), and paroxetine (Paxil, SmithKline Beecham Pharmaceuticals, Philadelphia, PA) belong to a new class of antidepressant medication: the serotonin reuptake-inhibitors (SRIs). The relative safety profile of the SRIs has led to their widespread use. However, a syndrome of excessive serotonergic activity, the ''serotonin syndrome'' (SS), has recently been recognized. It is characterized by changes in mental status, hypertension, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, and tremor. A high index of suspicion is required to make the diagnosis in these acutely ill patients. The most common agents implicated in SS are the monoamine oxidase inhibitors in combination with L-tryptophan or fluoxetine. A case of a patient with significant peripheral vascular disease who developed SS while taking paroxetine and an over-the-counter cold medicine is reported. There have been no prior reports of this interaction. Discontinuation of the offending agents, sedation, and supportive care are the mainstays of treatment. The interactions of serotonin with platelets and vascular endothelium are also discussed.
引用
收藏
页码:642 / 644
页数:3
相关论文
共 24 条
[1]  
Rapport, Green, Page, Serum vasoconstrictor, serotonin
[2]  
isolation and characterization., J Biol Chem, 176, pp. 1243-1251, (1948)
[3]  
Erspamer, Asero, Identification of Enteramine, the Specific Hormone of the Enterochromaffin Cell System, as 5-Hydroxytryptamine, Nature, 169, pp. 800-801, (1952)
[4]  
Laird, Lydiard, Morton, Et al., Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients., J Clin Psychiatry, 54, pp. 224-228, (1993)
[5]  
Sternbach, The serotonin syndrome., Am J Psychiatry, 148, pp. 705-713, (1991)
[6]  
Nierenberg, Semprebon, The central nervous system serotonin syndrome, Clinical Pharmacology and Therapeutics, 53, pp. 84-88, (1993)
[7]  
Jenner, Pratt, Marsden, Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT., Adv Neurol, 43, pp. 629-643, (1986)
[8]  
Gimenez-Roldan, Mateo, Yebenes, Clinical, Biochemical, and Pharmacological Observation in a Patient with Postasphyxic Myoclonus, Clinical Neuropharmacology, 11, pp. 151-160, (1988)
[9]  
Spigset, Mjorndal, Loveheim, Serotonin syndrome caused by a moclobemide-clomipramine interaction., BMJ, 306, (1993)
[10]  
Goldberg, Huk, Serotonin Syndrome From Trazodone and Buspirone, Psychosomatics, 2, (1992)